Quanterix (QTRX) Stock Price, News & Analysis

Company Overview

Quanterix Corporation (NASDAQ:QTRX) is a life sciences company that develops ultra-sensitive digital immunoassay technologies for detecting and measuring biomarkers in blood and other biological samples. Its platform is designed to identify proteins and other biomarkers at concentrations significantly below the capabilities of many conventional immunoassay methods, supporting research into disease biology, diagnosis, treatment development and monitoring.

The company’s primary technology, Simoa, is used in its laboratory instruments, assay kits, consumables and software products. Quanterix offers systems such as the HD-X, SR-X and SP-X platforms, along with assays for applications that include neurology, oncology, immunology, cardiology and infectious disease research. It also provides laboratory services and access to its technology for pharmaceutical, biotechnology, academic and clinical research organizations.

Quanterix was founded in 2007 by David Walt, a scientist and professor associated with Harvard University and the Wyss Institute. The company serves customers internationally through direct operations, commercial partners and distributors. Its corporate headquarters are in Billerica, Massachusetts, and Masoud Toloue serves as president and chief executive officer.

Key Stats

• Today's Range: $3.44 to $3.69
• 50-Day Range: $2.42 to $4.03
• 52-Week Range: $2.15 to $8.77
• Volume: 590,804 shs
• Average Volume: 892,274 shs
• Market Capitalization: $172.15 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.00
• Consensus Rating: Reduce

Quanterix Stock Analysis - MarketRank™

Quanterix scored higher than 12% of companies evaluated by MarketBeat, and ranked 837th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Reduce

Consensus Rating

Quanterix has received a consensus rating of Reduce. The company's average rating score is 1.67, and is based on no strong buy ratings, no buy ratings, 2 hold ratings, and 1 sell rating.

Downside Risk

Quanterix has a consensus price target of $3.00, representing about 17.6% downside from its current price of $3.64.

Amount of Analyst Coverage

Quanterix has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Quanterix is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Quanterix is -1.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Quanterix has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.68% of the float of Quanterix has been sold short.

Short Interest Ratio / Days to Cover

Quanterix has a short interest ratio ("days to cover") of 4.23.

Change versus previous month

Short interest in Quanterix has recently increased by 3.30%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Quanterix does not currently pay a dividend.

Dividend Growth

Quanterix does not have a long track record of dividend growth.

News and Social Media

• Score: 1.6 / 5
• News Sentiment: N/A

News Sentiment

Quanterix has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

MarketBeat Follows

Only 1 people have added Quanterix to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Quanterix insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.50% of the stock of Quanterix is held by insiders.

Percentage Held by Institutions

86.48% of the stock of Quanterix is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:QTRX
• CIK: 1503274
• Web: www.quanterix.com
• Phone: (617) 301-9400
• Fax: N/A
• Employees: 450
• Year Founded: 2007

Price Target and Rating

• Average Price Target for Quanterix: $3.00
• High Price Target: $3.00
• Low Price Target: $3.00
• Potential Upside/Downside: -17.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$107.15 million
• Net Margins: -80.25%
• Pretax Margin: -81.68%
• Return on Equity: -26.09%
• Return on Assets: -19.03%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.40
• Quick Ratio: 2.45

Sales & Book Value

• Annual Sales: $153.17 million
• Price / Sales: 1.12
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $6.33 per share
• Price / Book: 0.58

Miscellaneous

• Outstanding Shares: 47,293,000
• Free Float: 46,584,000
• Market Cap: $172.15 million
• Optionable: Optionable
• Beta: 1.01